



SFB 824  
Project A1


Vasilis Ntziachristos

Chair for Biological Imaging  
Institute for Biological and Medical Imaging


# WORKSHOP ON FMT-XCT

Hybrid Fluorescence  
Molecular Tomography –  
X-ray Computed Tomography System


introduction & reception




Thursday 24<sup>th</sup> November, 13:00  
Lecture Hall Pavillon  
Klinikum rechts der Isar  
Ismaninger Str. 22, 81675 Munich



(b)



(c)



Ale et. al. **Nature Methods** 9: 615–620 (2012)  
Ntziachristos V., **Nature Methods** 7(8); 603 (2010)  
Schulz et. al. **IEEE TMI** 29(2):465-73 (2010).

## ***In vivo* imaging of CT26 mouse tumours by using cmHsp70.1 monoclonal antibody**

Stefan Stangl<sup>a</sup>, Mathias Gehrmann<sup>a</sup>, Ralf Dressel<sup>b</sup>, Frauke Alves<sup>c</sup>, Christian Dullin<sup>d</sup>,  
George Themelis<sup>e</sup>, Vasilis Ntziachristos<sup>e</sup>, Eva Staebelin<sup>a</sup>, Axel Walch<sup>f</sup>,  
Isabel Winkelmann<sup>f</sup>, Gabriele Multhoff<sup>a, \*</sup>

Radiotherapy and Oncology 99 (2011) 313–316



Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: [www.thegreenjournal.com](http://www.thegreenjournal.com)



Molecular radiobiology








Detection of irradiation-induced, membrane heat shock protein 70 (Hsp70)  
in mouse tumors using Hsp70 Fab fragment

Stefan Stangl<sup>a</sup>, George Themelis<sup>b</sup>, Lars Friedrich<sup>c</sup>, Vasilis Ntziachristos<sup>b</sup>, Athanasios Sarantopoulos<sup>b</sup>,  
Michael Molls<sup>a</sup>, Arne Skerra<sup>c</sup>, Gabriele Multhoff<sup>a,\*</sup>

<sup>a</sup>Dept. of Radiation Oncology, TU München and Helmholtz Zentrum München (HMGU), CCG-Innate Immunity in Tumor Biology, Germany; <sup>b</sup>HMGU, Institute of Biological and Medical Imaging, Munich, Germany; <sup>c</sup>Munich Center for Integrated Protein Science, Technische Universität München, Freising-Weihenstephan, Germany

# FMT-PCCT imaging of the PDAC model

IntegriSense 680




**FMT-PCCT**



**Validation**




# Automatic cryoslicer imaging




Sarantopoulos et. al. Mol. Imag. Biol. 2010



# Bio-distribution





## cryosections




## C10 - Development of imaging approaches to monitor tumor-reactive T cells

### Spectral unmixing



Prof. Dr. Angela Krackhardt  
Dr. Calogero D'Alessandria


## Cy5 Observation



SMA-targeted hybrid probe PSMA-I&F for nuclear and fluorescence imaging of prostate cancer

*J. Nucl. Med.* 60(1):71-78, 2019


## Brown Fat



A dual Ucp1 reporter mouse model for imaging and quantification of brown and brite fat recruitment

*Mol. Metab.* 20:14-27, 2019

## ICG Unmixing




Therapeutic Fluorescent Hybrid Nanoparticles for Traceable Delivery of Glucocorticoids to Inflammatory Sites

*Theranostics* 8(22):6367-6383, 2018




## B5 - CXCR4-imaging in esophageal cancer - diagnosis and prognosis - *Dual wavelength FME system*




## FME in Z3 / Swine Colonoscopy

A protease-activated, near-infrared fluorescent probe for early endoscopic detection of premalignant gastrointestinal lesions



Biodegradable Fluorescent Nanoparticles for Endoscopic Detection of Colorectal Carcinogenesis





Proc Natl Acad Sci USA 2021 118(1):e2008072118

Adv Funct Mater 2019 29(51):1904992 (IF 16.8)


Gorpas, Saur, Ntziachristos, Schnieke,  
Rogalla, Contag, Gambhir, Harmsen, Bogoyo

# Early Detection of Lung Cancer




# Multispectral Optoacoustic Tomography

## Handheld MSOT for clinical translation



Nature Photonics 9, 219–227 (2015)




## NEW LABEL-FREE Imaging

- Oxygenation / Hypoxia
- Microvasculature, rarefaction
- Metabolism (rate of oxygen consumption)
- Inflammation (dilation, Hb concentration)
- Perfusion / Flow




# Multi-spectral opto-acoustic tomography (MSOT)



Nature Photonics 9, 219–227 (2015) 2015  
ACR Chemical Review, 110(5); 2783-2794 (2010)  
Nature Methods 7(8); 603-614, (2010)  
Nature Photonics 3, 412-417 (2009)


# Oxygenation quantification - eMSOT

Description of light fluence in the spectral domain




Tzoumas S., et. al Nature Comm. 2016


## SMALL ANIMAL IMAGING



## IMAGING METABOLISM




## IMAGING INFLAMMATION



**New England J. of Medicine 376:129 2017**  
**Nature Medicine 25, 1905–1915 (2019)**

## BREAST CANCER IMAGING

**Clin Cancer Res 23:6912 (2017)**




# Breast Cancer Imaging

Imaging Protocol

28 Wavelength  
Data Collection

Spectral Unmixing



Diot G., et. al. Clinical Cancer Research (2017)




# Breast Cancer Imaging

Imaging Protocol

28 Wavelength  
Data Collection

Spectral Unmixing



Diot G., et. al. Clinical Cancer Research (2017)

Article

# Mutation of the Cell Cycle Regulator p27kip1 Drives Pseudohypoxic Pheochromocytoma Development

Hermine Mohr <sup>1,2</sup>, Simone Balkle <sup>3</sup>, Nicole Bechmann <sup>4,5</sup>, Sebastian Gulde <sup>1,2</sup>, Jaber Malekzadeh-Najafabadi <sup>6</sup>, Mirko Peitzsch <sup>3</sup>, Vasilis Ntziachristos <sup>6,7</sup>, Katja Steiger <sup>3</sup>, Tobias Wiedemann <sup>1,2</sup> and Natalia S. Pellegata <sup>1,2,\*</sup>

- <sup>1</sup> Institute for Diabetes and Cancer, Helmholtz Centre Munich, Ingolstaedter Landstr. 1, 85764 Neuberg, Germany; hermine.mohr@helmholtz-muenchen.de (H.M.); sebastian.gulde@helmholtz-muenchen.de (S.G.); tobias.wiedemann@helmholtz-muenchen.de (T.W.)
- <sup>2</sup> Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, 69120 Heidelberg, Germany
- <sup>3</sup> Institute of Pathology, School of Medicine, Technical University Munich, Trogerstr. 18, 81675 Munich, Germany; simone.balkle@tum.de (S.B.); katja.steiger@tum.de (K.S.)
- <sup>4</sup> Department of Medicine III, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstrasse 74, 01307 Dresden, Germany; Nicole.Bechmann@uniklinikum-dresden.de
- <sup>5</sup> Institute of Clinical Chemistry and Laboratory, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstrasse 74, 01307 Dresden, Germany; Mirko.Peitzsch@uniklinikum-dresden.de
- <sup>6</sup> Chair of Biological Imaging, Technical University of Munich, Ismaninger StraÙe 22, 81675 Munich, Germany; jaber.malekzadeh@helmholtz-muenchen.de (J.M.-N.); vntziachristos@helmholtz-muenchen.de (V.N.)
- <sup>7</sup> Institute for Biomedical Imaging, Helmholtz Centre Munich, Ingolstaedter Landstr. 1, 85764 Neuberg, Germany

\* Correspondence: natalia.pellegata@helmholtz-muenchen.de; Tel.: +49-(0)89-3187-2633



**Citation:** Mohr, H.; Balkle, S.; Bechmann, N.; Gulde, S.; Malekzadeh-Najafabadi, J.; Peitzsch, M.; Ntziachristos, V.; Steiger, K.; Wiedemann, T.; Pellegata, N.S. et al. Mutation of the Cell Cycle Regulator p27kip1 Drives Pseudohypoxic Pheochromocytoma Development. *Cancers* **2021**, *13*, 126. <https://doi.org/10.3390/cancers13010126>

Received: 10 November 2020  
Accepted: 29 December 2020  
Published: 2 January 2021


**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).



**Simple Summary:** Pheochromocytomas and paragangliomas (PPGLs) can be subdivided into at least three different subgroups associated with different clinical manifestations and depending on the risk to metastasize. A shortage in human tumor material, the lack of a functional human cell line and very limited animal models were major drawbacks for PPGL research and consequently for the development of patient-tailored targeted therapies. We have previously reported that the MENX rat model develops pheochromocytoma with a full penetrance at the age of 8–10 months, however, it was unclear which human group the rat tumors modeled best. In order to characterize the rat pheochromocytomas, we analyzed gene expression, the catecholamine profile, TCA-cycle metabolism, methylation, angiogenesis, histology and mitochondrial ultrastructure. In all aspects, rat MENX pheochromocytomas resemble the features of the human pseudohypoxia group, the most aggressive one and in need of effective therapeutic approaches.

**Abstract:** Background: Pseudohypoxic tumors activate pro-oncogenic pathways typically associated with severe hypoxia even when sufficient oxygen is present, leading to highly aggressive tumors. Prime examples are pseudohypoxic pheochromocytomas and paragangliomas (p-PPGLs), neuroendocrine tumors currently lacking effective therapy. Previous attempts to generate mouse models for p-PPGLs all failed. Here, we describe that the rat MENX line, carrying a *Cdtn1b* (p27) frameshift-mutation, spontaneously develops pseudohypoxic pheochromocytoma (p-PCC). Methods: We compared rat p-PCCs with their cognate human tumors at different levels: histology, immunohistochemistry, catecholamine profiling, electron microscopy, transcriptome and metabolome. The vessel architecture and angiogenic potential of pheochromocytomas (PCCs) was analyzed by light-sheet fluorescence microscopy ex vivo and multi-spectral optoacoustic tomography (MSOT) in vivo. Results: The analysis of tissues at various stages, from hyperplasia to advanced grades, allowed us to correlate tumor characteristics with progression. Pathological changes affecting the mitochondrial ultrastructure were present already in hyperplasias. Rat PCCs secreted high levels of nonphenylephrine and dopamine. Transcriptomic and metabolomic analysis revealed changes in oxidative phosphorylation that aggravated over time, leading to an accumulation of the oncometabolite 2-hydroxyglutarate, and to hypermethylation, evident by the loss of the epigenetic mark 5-hmC. While rat PCC xenografts showed high oxygenation, induced by massive neoangiogenesis, rat primary PCC transcriptomes





# Rhodobacter (purple bacteria) as a marker for Macrophage activity in vivo




Peters L, et. L. *Nature Communications*. 2019. 10(1):1191.




# Bacteria derived vesicles – agents with diagnostic and therapeutic perspective:

*E. Coli* producing vesicles containing melanin (▲)


Melanin vesicle (OMV<sup>Mel</sup>)



Optoacoustic tumor imaging  
using OMV<sup>Mel</sup>



Photothermal effect of  
OMV<sup>Mel</sup>




Gujrati V, et. al. *Nature Communications*. 2019. 10(1):1114.




# Imaging of PDT effects

Coleman Group, Grimm, Kircher groups - MSKCC  
Avigdor Scherz – Weizmann Institute



Volker Neuschmelting, Kwanghee Kim, Jaber Malekzadeh

SFB | **824**



ABOUT THE SFB  
RESEARCH AREAS  
TEAM

- Organization & Steering Committee
- Principal Investigator
- Staff

GENDER PROGRAM  
PUBLICATIONS  
NEWS & EVENTS  
CAREER  
COOPERATION

HOME » TEAM » ORGANIZATION & STEERING COMMITTEE

## ORGANIZATION & STEERING COMMITTEE

### SFB 824 Speaker

Prof. Dr. med. Markus Schwaiger  
Clinic on the right of the Isar TU Munich  
medical director  
Ismaninger Strasse 22  
81675 Munich

Phone: +49 89 4140-7700  
Fax: +49 89 4140-7709  
Email: [markus.schwaiger@tum.de](mailto:markus.schwaiger@tum.de)

### SFB 824 coordinator

Thorsten Geerken  
Clinic on the right of the Isar TU Munich  
TranslaTUM  
Einstein Street 25  
81675 Munich

Phone: +49 89 4140-4574  
Fax: +49 89 4140-9191  
Email: [thorsten.geerken@mri.tum.de](mailto:thorsten.geerken@mri.tum.de)

### SFB 824 Steering Committee

Prof. Dr. med. Markus Schwaiger  
medical director  
Clinic on the right of the Isar TU Munich

Prof. Dr. Gabriele Multhoff  
Clinic and Polyclinic for Radiation Therapy and Radiological Oncology  
Clinic on the right of the Isar TU Munich

Prof. Dr. Vasilis Ntzachristos  
Department of Biological Imaging  
Technical University of Munich

Prof. Dr. Hans-Jürgen Wester  
Chair of Radiopharmaceutical Chemistry

Prof. Dr. med. Wilko Weichert  
Institute for General Pathology and Pathological Anatomy  
Technical University of Munich

Prof. Dr. Wolfgang Weber  
Clinic and Polyclinic for Nuclear Medicine  
Clinic on the right of the Isar TU Munich

## EVENTS

04/02/2020 09:00  
**IN VIVO MAGNETIC  
RESONANCE - RECENT  
METHODS AND  
ADVANCES**

[MORE INFORMATION](#)

04/01/2020 3:30 p.m.  
**"RADIOTHERAGNOSTICS  
IN CANCER RESEARCH -  
TERBIUM SISTERS AND  
BEYOND"**

[MORE INFORMATION](#)

03/28/2019 00:00  
**GIRLS' DAY OFFER IN  
THE TRANSLATUM**

[MORE INFORMATION](#)

06.03.2019 11:30  
**HSP110 AS A  
THERAPEUTIC TARGET  
IN COLORECTAL  
CANCER: FROM  
CRYSTALS TO DRUG  
SELECTION**

[MORE INFORMATION](#)



Future SFB